Transplantation for amyloidosis

Morie A. Gertz; Martha Q. Lacy; Angela Dispenzieri; Suzanne R. Hayman; Shaji Kumar

doi:10.1097/CCO.0b013e32801494c6

Transplantation for amyloidosis

Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Shaji Kumar

Hematology

Research output: Contribution to journal › Review article › peer-review

72 Scopus citations

Abstract

PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.

Original language	English (US)
Pages (from-to)	136-141
Number of pages	6
Journal	Current Opinion in Oncology
Volume	19
Issue number	2
DOIs	https://doi.org/10.1097/CCO.0b013e32801494c6
State	Published - Mar 2007

Keywords

Amyloidosis
Multiple myeloma
Nephrotic syndrome
Restrictive cardiomyopathy
Stem cell transplantation

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/CCO.0b013e32801494c6

Cite this

@article{cb163cbc119d42f2a3a29fda9a92372e,

title = "Transplantation for amyloidosis",

abstract = "PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.",

keywords = "Amyloidosis, Multiple myeloma, Nephrotic syndrome, Restrictive cardiomyopathy, Stem cell transplantation",

author = "Gertz, {Morie A.} and Lacy, {Martha Q.} and Angela Dispenzieri and Hayman, {Suzanne R.} and Shaji Kumar",

year = "2007",

month = mar,

doi = "10.1097/CCO.0b013e32801494c6",

language = "English (US)",

volume = "19",

pages = "136--141",

journal = "Current Opinion in Oncology",

issn = "1040-8746",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Transplantation for amyloidosis

AU - Gertz, Morie A.

AU - Lacy, Martha Q.

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Kumar, Shaji

PY - 2007/3

Y1 - 2007/3

N2 - PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.

AB - PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.

KW - Amyloidosis

KW - Multiple myeloma

KW - Nephrotic syndrome

KW - Restrictive cardiomyopathy

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=33846828703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846828703&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32801494c6

DO - 10.1097/CCO.0b013e32801494c6

M3 - Review article

C2 - 17272986

AN - SCOPUS:33846828703

SN - 1040-8746

VL - 19

SP - 136

EP - 141

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

IS - 2

ER -

Transplantation for amyloidosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this